ABT
HealthcareAbbott Laboratories · Medical - Devices · $184B
What is Abbott Laboratories?
Abbott Laboratories is a global healthcare company operating across diagnostics, medical devices, nutrition, and established pharmaceuticals. Its products reach patients and clinicians in markets worldwide.
Abbott generates revenue across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company sells laboratory systems, rapid diagnostics tests, point-of-care devices, nutritional formulas, and a broad range of generic medicines — serving hospitals, clinics, and consumers globally.
Abbott has been headquartered in Abbott Park, US, with its current corporate structure dating to 1980.
- Diagnostic laboratory and point-of-care systems
- Medical devices for cardiac and vascular care
- Nutritional products for infants and adults
- Established generic pharmaceuticals
Is ABT a Good Stock to Buy?
UQS Score rates ABT as Good overall.
Abbott's strongest pillar signals come from Risk and Valuation, suggesting the stock carries below-average downside risk relative to peers and sits at a relatively attractive price level for the healthcare sector.
Quality, Moat, and Growth all register as Neutral, indicating Abbott does not stand out decisively on competitive positioning or near-term expansion relative to large-cap healthcare peers.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ABT pay dividends?
Yes — Abbott Laboratories pays a dividend.
Abbott pays a regular dividend, consistent with its long history as a large-cap healthcare company. The dividend reflects stable cash generation across its diversified business segments. Income-oriented investors often view Abbott's dividend track record as a meaningful part of the total return picture.
When does ABT report earnings?
Abbott Laboratories reports earnings on a quarterly cadence, typical for US-listed large-cap equities.
Abbott's diversified revenue base — spanning diagnostics, devices, nutrition, and pharmaceuticals — means quarterly results can reflect varying demand trends across each segment. Diagnostic volumes and medical device procedure rates are common focal points each reporting period.
For the most recent quarter's results and guidance, visit Abbott Laboratories' investor relations page directly.
ABT Price History
-13.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Abbott Laboratories?
Based on Abbott Laboratories's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Abbott Laboratories do?
Abbott discovers, develops, manufactures, and sells healthcare products worldwide. Its four business segments cover diagnostic systems, medical devices, nutritional products, and established generic pharmaceuticals — serving hospitals, clinics, and consumers across global markets.
Does ABT pay dividends?
Yes, Abbott pays a regular dividend. The company has a long history of returning cash to shareholders through dividends, supported by its diversified and relatively stable revenue streams across healthcare segments.
When does ABT report earnings?
Abbott reports on a standard quarterly schedule. For the exact date of the next earnings release, check Abbott's official investor relations page, as dates can shift and our platform does not publish forward earnings calendars.
Is ABT a good stock to buy?
UQS Score rates ABT as Good. The Risk and Valuation pillars are the relative strengths, while Quality, Moat, and Growth are Neutral. Whether ABT fits your portfolio depends on your own goals — the full pillar breakdown is available to Pro members.
Is ABT overvalued?
The UQS Valuation pillar for ABT is rated Good, suggesting the stock is not considered elevated relative to its fundamentals at the time of scoring. Valuation assessments can shift with market conditions, so checking the latest score is worthwhile.
What is ABT's market cap bracket?
Abbott Laboratories is a large-cap company, placing it among the more established and widely held names in the global healthcare sector.
Is ABT a long-term quality indicator?
Abbott's UQS profile shows Good overall quality with neutral readings on Moat and Growth — factors that matter for long-term compounding. Its diversified healthcare model and dividend history are relevant considerations, but investors should review the full analysis before drawing conclusions.
What sector does ABT belong to?
Abbott Laboratories operates in the Healthcare sector, with exposure across diagnostics, medical devices, nutrition, and pharmaceuticals — giving it broader diversification than many single-focus healthcare peers.
Unlock Full ABT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings for ABT
- ✓Access full financial metrics and trend data
- ✓Compare ABT side-by-side with Stryker, Medtronic, and Boston Scientific
- ✓Screen the healthcare sector by Quality, Risk, and Valuation
Pro Analysis
ABT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | 49.0 | 51.3 | 46.0 | 45.7 | 43.7 | 59.8 | 0.0 |
| Jul 27, 2026 | 49.0 | 50.4 | 46.0 | 45.7 | 43.9 | 60.9 | 0.0 |
| Jul 25, 2026 | 49.0 | 50.4 | 46.0 | 45.7 | 43.9 | 61.4 | -0.4 |
| Jul 24, 2026 | 49.4 | 50.6 | 46.0 | 45.7 | 43.9 | 63.4 | -0.1 |
| Jul 23, 2026 | 49.5 | 50.6 | 46.0 | 45.7 | 43.9 | 63.8 | -1.6 |
| Jul 22, 2026 | 51.1 | 53.2 | 46.0 | 45.7 | 47.2 | 67.0 | +0.2 |
| Jul 21, 2026 | 50.9 | 53.0 | 46.0 | 45.7 | 47.2 | 66.3 | -0.2 |
| Jul 19, 2026 | 51.1 | 53.1 | 46.0 | 45.7 | 47.2 | 67.1 | 0.0 |
| Jul 18, 2026 | 51.1 | 53.1 | 46.0 | 45.9 | 47.2 | 67.0 | -1.1 |
| Jul 17, 2026 | 52.2 | 54.8 | 46.0 | 46.1 | 50.1 | 68.2 | -0.9 |
ABT — Pillar Breakdown
Quality
— 51.3/100 (25%)Abbott Laboratories has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 45.7/100 (20%)Abbott Laboratories shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 43.7/100 (15%)Abbott Laboratories has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 59.8/100 (15%)Abbott Laboratories trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 46/100 (25%)Abbott Laboratories possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ABT.
Score Composition
Financial Data
More Stock Analysis
How is the ABT UQS Score Calculated?
The UQS (Unified Quality Score) for Abbott Laboratories is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Abbott Laboratories's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Abbott Laboratories is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.